期刊
CANCER CELL
卷 39, 期 12, 页码 1578-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2021.09.010
关键词
-
资金
- Beijing Municipal Science and Technology Commission [Z201100005320014]
- National Key R&D Program of China [2020YFA0803300, 2018YFC1312101]
- National Natural Science Foundation of China [82030089, 81988101, 91942307, 31991171]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001, 2017-I2M-3004, 2019-I2M-1-003]
- Non-profit Central Research Institute Fund of CAMS [2019PT310027]
- Capital's Funds for Health Improvement and Research [CFH2018-4-4024]
- Boya Postdoctoral Foundation of Peking University
The study indicates that high levels of baseline CXCL13(+) T cells are associated with effective responses to combination therapy in triple-negative breast cancer patients. These cells increase following combination therapy but decrease after monotherapy, highlighting their importance in predicting treatment outcomes.
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine the immune cell dynamics in 22 patients with advanced TNBC treated with paclitaxel or its combination with the anti-PD-L1 atezolizumab. We demonstrate that high levels of baseline CXCL13(+) T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy. In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13(+) T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy. Our data highlight the importance of CXCL13(+) T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据